Protocol Ledger

NCT05993143 · Phase III · TERMINATED

Ivermectin to Prevent SARS-CoV-2 (COVID-19) Hospitalisation in Subjects Over 50

Interventional Phase III clinical trial protocol NCT05993143 sponsored by Insud Pharma in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-01-18 Enrollment: 249 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05993143
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)249 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05993143
Protocol FieldVerified Registry Value
NCT IdentifierNCT05993143
Consolidated Lead SponsorInsud Pharma
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment249 participants (ACTUAL)
Registered Start Date2021-01-18
WhyStopped ClassificationLack of Efficacy / Futility

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI